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Abstract
Aims: The tendency to develop diabetic nephropathy is, in part, genetically determined, however this genetic risk is largely
undefined. In this proof-of-concept study, we tested the hypothesis that combined analysis of multiple genetic variants can
improve prediction.
Methods: Based on previous reports, we selected 27 SNPs in 15 genes from metabolic pathways involved in the
pathogenesis of diabetic nephropathy and genotyped them in 1274 Ashkenazi or Sephardic Jewish patients with Type 1 or
Type 2 diabetes of .10 years duration. A logistic regression model was built using a backward selection algorithm and SNPs
nominally associated with nephropathy in our population. The model was validated by using random ‘‘training’’ (75%) and
‘‘test’’ (25%) subgroups of the original population and by applying the model to an independent dataset of 848 Ashkenazi
patients.
Results: The logistic model based on 5 SNPs in 5 genes (HSPG2, NOS3, ADIPOR2, AGER, and CCL5) and 5 conventional
variables (age, sex, ethnicity, diabetes type and duration), and allowing for all possible two-way interactions, predicted
nephropathy in our initial population (C-statistic=0.672) better than a model based on conventional variables only
(C=0.569). In the independent replication dataset, although the C-statistic of the genetic model decreased (0.576), it
remained highly associated with diabetic nephropathy (x
2=17.79, p,0.0001). In the replication dataset, the model based
on conventional variables only was not associated with nephropathy (x
2=3.2673, p=0.07).
Conclusion: In this proof-of-concept study, we developed and validated a genetic model in the Ashkenazi/Sephardic
population predicting nephropathy more effectively than a similarly constructed non-genetic model. Further testing is
required to determine if this modeling approach, using an optimally selected panel of genetic markers, can provide clinically
useful prediction and if generic models can be developed for use across multiple ethnic groups or if population-specific
models are required.
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Introduction
Diabetes Mellitus (DM) is a serious metabolic disorder,
characterized by defects in both insulin secretion and action.
The prevalence of the disease, which is becoming a major world-
wide health problem, is increasing rapidly [1]. As a result of
diabetes-associated metabolic dysregulation, many patients with
type 1 and type 2 diabetes (T1DM and T2DM) develop multi-
organ micro- and macro-vascular complications. These complica-
tions are the primary cause of kidney failure, adult-onset blindness
and non-traumatic leg amputations in the western world [2].
Thus, diabetes and diabetic complications, particularly nephrop-
athy, place an enormous burden on health care systems [3].
Although control of the abnormal metabolic state associated
with both types of diabetes has a major impact on the incidence
and severity of nephropathy, the propensity to develop this
complication is, in part, genetically determined [4,5]. As many as
25% of diabetic individuals will never develop clinical evidence of
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18743nephropathy regardless of metabolic control [As reviewed by 5].
Ethnicity plays an important role in the risk of developing diabetic
nephropathy as evidenced by some racial and ethnic minorities,
such as Pima Indians, Nauruan, Asian Indians, African-Americans
and Mexican-Americans, having an unusually high burden of the
disease [6,7]. Familial clustering of nephropathy also suggests a
strong genetic component to the risk of disease [8,9,10,11].
Quantitative measures for traits related to diabetic nephropathy
have exhibited moderate to high estimated heritability (h
2): 0.30 to
0.44 for albumin-creatinine ratio (ACR) [12,13,14,15,16] and 0.36
to 0.75 for glomerular filtration rate (GFR) [14,17,18]. Further-
more, studies of identical twins suggest a genetic component in the
pathogenesis of nephropathy in T2DM, and less so in T1DM [19].
Over the last 20 years multiple studies have identified linkage
peaks in various regions of the genome or have demonstrated
associations between genetic variants in different genes and diabetic
complications, particularly nephropathy [20,21]. Taken together,
these studies clearly show that there is no single genetic factor that
has a major effect on risk of diabetic complications in the
population. Therefore, for risk prediction to be clinically useful, a
composite model is needed that estimates the combined effect of
‘‘conventional’’ risk factors and genetic variants in multiple genes
coding for proteins acting alone or interacting with each other [22].
The probability of identifying meaningful gene-gene interac-
tions may be enhanced by selecting genes in well-defined
metabolic or functional pathways that are thought to be important
in the pathogenesis of the disease. For this reason, we selected
genes associated with 4 metabolic pathways that are thought to
play an important role in diabetic nephropathy. The methionine
metabolic pathway was selected since, in addition to the potential
direct cellular toxicity of high homocysteine (HCY) levels,
nephrotoxicity can be caused through different mechanisms
activated by this pathway including thrombotic effects and
vascular damage [23]. The adiponectin pathway was selected
since adiponectin levels vary in different diabetic complications
making it and the genes that are responsible for its control,
potentially important in the pathogenesis of nephropathy [24].
The renin-aldosterone pathway was selected since it is responsible
for the blood pressure regulation, which in turn influences renal
damage [25,26,27]. Finally, the AGEs (advanced glycation end
products) pathway was selected since AGEs production and
oxidative stress play an important role in the development of
complications [28]. Cytokines such as CCL5 (chemokine (C-C
motif ligand 5), also known as RANTES, bind to their receptors in
renal tissue and cause macrophage activation [29,30,31].
In this study, we selected a panel of single nucleotide
polymorphisms (SNPs) from these 4 major pathways that were
previously found to be associated with risk of diabetic nephropathy
in multiple populations. After determining which of these SNPs
approach nominal association with disease in our population, we
Table 1. Clinical and demographic characteristics of the subjects meeting all inclusion criteria and having DNA available for
genotyping.
Primary Population Replication Population
Between
Population
p3
Nephropathy
1
No
Nephropathy p
2 Nephropathy
No
Nephropathy p
2
Demographic Characteristics
Total number 556 (38.9%) 873 (61.1%) 296 (32.7%) 610 (67.3%) 0.0023
4
Male (%) 46.9 46.4 0.8278 52.7 44.8 0.0282 0.7019
Age
5 62.6611.2 64.1611.4 0.0147 61.7614.9 58.3617.9 0.0026 ,0.0001
Age at DM Diagnosis
5 42.7613.1 43.8612.6 0.1304 40.1617.7 38.7618.9 0.2045 ,0.0001
Ethnic background
Ashkenazi Jews (%) 69.4 71.6 0.4038 100 100 — —
Non-Ashkenazi Jews (%) 30.6 28.4 - -
Clinical characteristics
Years of DM
5 19.868.6 20.368.8 0.3498 21.669.8 19.668.9 0.0032 0.5923
HbA1c (%)
5 8.061.5 8.161.6 0.4553 8.5261.58 8.1261.45 0.0003 0.003
Hypertension (%) 65.1 63.1 0.6824 67.6 41.5 ,0.0001 ,0.0001
BMI (kg/m2)
5 29.164.5 29.9 65.8 0.008 27.064.9 28.565.3 0.0607 ,0.0001
T2DM (%) 91.2 83.4 ,0.0001 75.3 64.4 0.0011 ,0.0001
Complications
Retinopathy (%)
6 18.5 18.2 0.7776 58.8 24.6 ,0.0001 ,0.0001
CHD (angina, CABG, PCI or MI) (%)
7 30.0 47.5 ,0.0001 37.5 27.5 0.0019 0.0007
1. Nephropathy = microalbinuria or proteinuria or end-stage renal disease (dialysis) due to diabetic nephropathy.
2. p value comparing Nephropathy and No-Nephropathy subsets of same population.
3. p value comparing total primary population to total Replication Population.
4. p value comparing prevalence of nephropathy in the 2 populations.
5. Age, age at DM diagnosis, years of DM, HbA1c, BMI are expressed in mean 6 SD.
6. Retinopathy = For primary population retinopathy defined as proliferative retinopathy or macular edema; For replication population retinopathy defined as
background or proliferative retinopathy or macular edema.
7. CHD = coronary heart disease, CABG = coronary artery bypass graft, PCI = percutaneous coronary intervention, MI = Myocardial infarction.
doi:10.1371/journal.pone.0018743.t001
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variant and conventional risk factor alone and all possible two-way
interactions. This model predicted nephropathy in our initial
population, a finding that was replicated in an independent,
ethnically similar population ascertained in Israel.
Materials and Methods
Patient populations
Ethics Statement. This protocol was approved by the Ethics
Committees on Human Research in Hadassah-Hebrew University
Medical Center, Wolfson Medical Center and Soroka Medical
Center. Written informed consent was obtained from all participants.
Primary study populations. Patients with diabetes were
ascertained by the Israel Diabetes Research Group between 2002
and 2004 from 15 diabetes clinics throughout Israel. Primary
admission criteriawere: (1) known diabetes (Type 1 orType 2) for 10
or more years and (2) ethnic background, as defined by all 4
grandparents being either Ashkenazi or Sephardic-North African
Jewish. Blood samples and clinical data from 1946 patients were
collected. Of these, 534 samples were excluded for not fulfilling
inclusion criteria, insufficient clinical data or for technical reasons
such as insufficient or poor quality DNA. The clinical and
demographic characteristic of the remaining 1412 subjects whose
DNA was submitted for genotyping are shown in Table 1. Briefly,
the overall prevalence of nephropathy was 38.9%. The majority
of the patients had T2DM, which was somewhat more
common in the group with nephropathy (91.2% and 83.4% in the
nephropathy and non-nephropathy subsets respectively, p,0.001).
Most subjects in both groups were of Ashkenazi origin (69.4% and
71.6% respectively, p=0.40). The patients with nephropathy were
slightly younger and thinner than those without nephropathy,
although duration of diabetes was not significantly different in the 2
groups. Of these patients, 138 were subsequently excluded because
of unsuccessful genotyping at one or more loci, leaving 1274 subjects
whose data were used for model construction.
Table 2. Genes/Pathways/SNPs studied.
Pathway Gene SNP rs_number MAF
1
MAF
Cases
MAF
Contr.
Allelic Assoc.
2
p= OR (95% CI)
3
Logistic
Regress.
4 p=
Vascular endothelial
function/damage
pathway
MTHFR 677C/T rs1801133 0.43 0.43 0.44 0.73 0.96 (0.83, 1.12) 0.63
1298A/C rs1801131 0.31 0.30 0.31 0.65 0.99 (0.84, 1.16) 0.87
MTR 2756A/G rs1805087 0.17 0.17 0.16 0.72 1.04 (0.85, 1.27) 0.69
CBS 1080C/T rs1801181 0.35 0.34 0.35 0.59 0.94 (0.79, 1.11) 0.46
1985T/C rs706208 0.40 0.40 0.39 0.87 0.99 (0.85, 1.14) 0.86
C699T rs234706 0.33 0.34 0.32 0.36 1.09 (0.93, 1.29) 0.28
844ins68 rs72058776 0.05 0.05 0.05 0.79 1.12 (0.78, 1.60) 0.54
HSPG2
5 HSPG2 A/C rs3767140 0.16 0.18 0.14 0.0066 1.31 (1.07, 1.61) 0.0085
NOS3
5 1917G/T rs1799983 0.23 0.21 0.24 0.0289 0.84 (0.70, 1.00) 0.0541
Adiponectin pathway PPARG Pro12Ala rs1801282 0.05 0.04 0.05 0.32 0.82 (0.56, 1.20) 0.30
ADIPOQ +45 T/G rs2241766 0.20 0.21 0.19 0.20 1.17 (0.97, 1.41) 0.10
+276 G/T rs1501299 0.31 0.32 0.31 0.59 1.02 (0.87, 1.20) 0.77
+712 G/A rs3774261 0.48 0.50 0.48 0.43 1.09 (0.92, 1.30) 0.33
-11391G/A rs17300539 0.11 0.12 0.11 0.36 1.09 (0.85, 1.38) 0.50
-11377 G/C rs266729 0.25 0.25 0.25 0.96 1.02 (0.86, 1.21) 0.84
ADIPOR1 -102 T/G rs2275737 0.47 0.46 0.48 0.44 1.07 (0.92, 1.25) 0.39
+5,843 A/G rs1342387 0.47 0.46 0.47 0.42 0.94 (0.81, 1.10) 0.47
ADIPOR2
5 +219 A/T rs11061971 0.48 0.51 0.46 0.0176 1.21 (1.04, 1.41) 0.0135
+33,447C/T rs1044471 0.47 0.45 0.48 0.10 0.88 (0.76, 1.03) 0.10
Renin pathway AGT M235T rs699 0.43 0.44 0.43 0.51 0.96 (0.82, 1.12) 0.57
ACE I/D rs4304 0.36 0.36 0.35 0.55 0.96 (0.82, 1.13) 0.61
AGTR1 A116C rs1064536 0.30 0.29 0.31 0.33 0.92 (0.78, 1.09) 0.32
AGER pathway AGER
5 1704G/T Y18060 0.23 0.22 0.23 0.29 0.91 (0.75, 1.09) 0.30
G82S rs2070600 0.01 0.01 0.01 0.68 1.18 (0.62, 2.69) 0.69
2184A/G rs3134940 0.13 0.15 0.11 0.0049 1.35 (1.08, 1.69) 0.0079
CCL5
5 -28C/G rs2280788 0.01 0.02 0.01 0.0645 1.93 (0.99, 3.77) 0.0531
CCR5 -59029G/A rs1799987 0.47 0.45 0.48 0.16 1.11 (0.95, 1.30) 0.18
1. MAF = Minor allele frequency determined in this dataset.
2. p values for unadjusted association with nephropathy.
3. Odds ratios are given for the comparison between the rare and common alleles. CI denotes confidence interval.
4. p value for logistic regression analysis adjusting for age, sex, duration of diabetes and type of diabetes.
5. SNPs included in the model are shown in bold.
doi:10.1371/journal.pone.0018743.t002
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T2DM from the Hebrew University Genetic Resource (HUGR)
collection (http://hugr.huji.ac.il/) were used as a validation dataset. Of
a total of 1639 patients available, only 906 fulfilled our inclusion
criteria, which included at least 10 years known duration of diabetes.
The prevalence of nephropathy in this dataset was somewhat lower
when compared to our initial dataset (32.7% vs 38.9%, p=0.0023) as
was the prevalence of T2DM. Age at ascertainment, age at diagnosis
and BMI were slightly, albeit significantly lower in this dataset when
compared to the primary population (Table 1). The apparent marked
increased incidence ofretinopathyinthe validation population isdue to
the fact that in this population the definition of retinopathy included
background retinopathy whereas in the initial population background
retinopathy was excluded from this diagnosis. Complete clinical and
genotype data required for analysis was available on 848 of these
patients.
Definition of nephropathy
For both the original and replication populations, nephropathy
was defined as the presence of microalbinuria (0.03-0.3 g/gr
creatinine), proteinuria (.0.3 g/gr creatinine) or dialysis in the
absence of any other unrelated renal disease.
Selection of genetic variants for analysis
The target candidate genes were selected according to
metabolic pathways thought to be important in the pathogenesis
of nephropathy (Table 2). A list of genetic variants within each
gene was generated based on previously reported associations with
nephropathy in other populations. This list was further restricted
using the haplotype structure of the Caucasian population (CEU)
in HapMap version 2 to avoid redundancy and to maximize
coverage of each gene. Thus, for some genes, SNPs previously
shown to be associated with nephropathy were excluded since they
were adequately represented by other SNPs in high LD (r
2.0.8).
Genotyping
Twenty-seven variants in 15 different genes in the original
dataset were individually genotyped using either PCR-RFLP or
ABI Taqman
TM assays. The genotyping of the validation dataset
was carried out using the KASPar technology (a competitive
allele specific PCR-based assay) by KBioscience (http://www.
kbioscience.co.uk). Hardy-Weinberg equilibrium was evaluated
using a standard one degree of freedom, two-tail x
2 test. The
genotype successful call rate for the whole replication set (cases and
controls) was 98.6% and no deviation from Hardy–Weinberg
equilibrium was observed (at p=0.05). The concordance between
Taqman and KASPar-based genotyping was previously shown to
be .99.5% with an error rate of ,0.3%.
Statistical analysis and modeling
Between group comparisons. Continuous variables were
compared using the two-tailed t-test and are reported as
average6SD. Discrete variables were compared using the two-
tailed Fisher Exact Test.
Individual genotype association. After demonstrating that all
SNPs were in Hardy-Weinberg equilibrium, each of the 27 SNPs was
tested for association with diabetic nephropathy in an additive model
by multivariable logistic regression analysis adjusting for age, sex,
duration of diabetes and type of diabetes (Table 2). Five variants that
approached nominally significant association withnephropathy inthe
primary dataset (uncorrected p value ,0.055) were genotyped in the
validation dataset. Analysis for association with nephropathy in the
validation dataset was performed as for the primary dataset.
Modeling. Before performing the logistic regression modeling,
we recoded the genotype results to avoid loss of information for either
heterozygotes or minor allele homozygotes and at the same time to
distinguish between them. For each SNP we split the genotype result
into two separate variables depending on the genotype result, the first
defined as equal to 1 if the result is heterozygote and equal to 0 in all
other cases (‘‘het’’ in Fig. 1 and Table 3), and the second defined as
equal 1 if the result is homozygous for minor allele and equal 0 in any
other cases (‘‘hom’’ in Fig. 1 and Table 3). The probability of
nephropathy was calculated using the equation:
P~
eazb0x
1zeazb0x
Where P is the probability of nephropathy, a is the intercept
parameter, b is the vector of regression parameters and X is a
matrix of the data.
Figure 1. The multifactorial model: ORs and 95% CI for different SNPs and interactions in the model (expressed in logarithmic
form). For the exact values see estimates in Table 3. All variables, single or interactions, contribute to the model significantly, but in different ways.
doi:10.1371/journal.pone.0018743.g001
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above (9 variables, since rs2280788 has MAF =0.01 to 0.02 and thus
no minor allele homozygotes) and 5 independent ‘‘conventional’’
nephropathy predictors: diabetes type, sex of the patient, age, duration
of diabetes and ethnicity. The model also allowed all possible
interactions of the second degree. The best logistic regression model
was chosen by the backward selection method. The final model
included variables and interactions that were significant on the Wald
Chi-square test as well as all variables included in the interaction terms
even if these did not reach statistical significance on their own [32].
Receiver Operating Characteristic (ROC) curves were generated. To
determine the impact of the genetic information on the final model,
the same procedure was repeated including only the five independent
‘‘conventional’’variables,allowingforall possible interactions between
them. All statistical analysis was done using SAS version 9.1.
Model validation
The model was validated internally and externally. First, the
primary population was randomly divided into two groups,
consisting of 75% and 25% of the study population. The larger
group was used as a ‘‘training set’’ and the resulting model was
validated on the smaller ‘‘test set’’. Next, the model generated in
the primary population was applied to the independent validation
population of similar ethnic and environmental background.
Results
Association of individual variants with nephropathy
For 5 of the 27 SNPs, each representing one gene, nominal p-
values obtained for association between nephropathy warranted
inclusion in the model (Table 2). Although there were some
Table 3. Model parameters with and without genetic factors.
Parameter1 Analysis of Maximum Likelihood Estimates
Estimate
2 Standard Error
3 Wald Chi-Square
4 Pr . ChiSq
5
‘‘Full’’ model
Intercept
6 0.4925 0.4222 1.3608 0.2434
ADIPOR2(het) 0.1353 0.2059 0.4317 0.5112
ADIPOR2(hom) 0.1572 0.2742 0.3288 0.5663
Age -0.0137 0.00556 6.0234 0.0141
AGER(het) -0.4843 0.3674 1.7379 0.1874
AGER(hom) 1.4179 0.5109 7.7038 0.0055
CCL5(het) 2.5223 0.6635 14.4493 0.0001
ADIPOR2(het) * CCL5(het) -2.9026 0.8759 10.9815 0.0009
YearsDM -0.00591 0.00980 0.3638 0.5464
AGER(het) * YearsDM 0.0332 0.0166 3.9693 0.0463
NOS3(het) -0.0251 0.1486 0.0286 0.8656
NOS3(het) * ADIPOR2(hom) -0.7647 0.3027 6.3811 0.0115
NOS3(hom) -0.3308 0.4004 0.6826 0.4087
NOS3(hom) * ADIPOR2(het) -1.3251 0.5876 5.0866 0.0241
NOS3(hom) * AGER(het) 1.4467 0.6326 5.2296 0.0222
Gender (fem) -0.6859 0.2393 8.2160 0.0042
ADIPOR2(het) *gender(fem) 0.7274 0.2947 6.0912 0.0136
ADIPOR2(hom) *gender(fem) 1.1368 0.3483 10.6493 0.0011
HSPG2(het) 0.8907 0.3650 5.9547 0.0147
HSPG2(het) * yearsdm -0.0383 0.0179 4.5697 0.0325
HSPG2(hom) 0.9661 0.3443 7.8708 0.0050
Typedm(T1DM) -0.1090 0.3517 0.0960 0.7567
Origin01(Ashk) -0.0615 0.1422 0.1870 0.6655
Typedm(T1DM) * Origin01(Ashk) -0.9075 0.4329 4.3960 0.0360
‘‘Conventional’’ model
Intercept
6 0.2865 0.3116 0.8457 0.3578
Age -0.0103 0.00486 4.5265 0.0334
Typedm1 -0.7771 0.1864 17.373 ,.0001
1– The intercept and the predictor variables in the model. – see Statistical Analysis and Modeling section for description of how the variables were coded.
2– Binary logit regression estimates for the parameters in the model. In the logistic regression equation log[p/(1-p)]= a+bx where p is the probability that nephropathy
= 1, the estimate of each variable contributes to b.
3– Standard errors of the individual regression coefficients.
4– Test statistic; the squared ratio of the Estimate to the SE of the respective predictor.
5- The probability that a particular Chi-Square test statistic (1 df) is as extreme as, or more so, than what has been observed under the null hypothesis; the null
hypothesis is that all of the regression coefficients in the model are equal to zero. The numbers in the column are the associated p-values.
6– The logistic regression estimate when all variables in the model are evaluated at zero. In the above equation intercept contributes to the a-coefficient.
doi:10.1371/journal.pone.0018743.t003
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(Ashkenazi, Sephardic or mixed); there are no differences in
complication incidence among these groups, and the p values for
the 5 SNPs remained essentially unchanged after adjusting for
ethnicity. Thus, these 5 SNPs were used for constructing the model
and for replication studies.
Model
The best-fit model retained 9 two-way interactions, 2 of the 4
‘‘conventional’’ variables (sex and age) and 3 of the 5 SNPs as
significant independent variables. In addition, 9 independent
variables that were included in the interaction terms but were not
independently significant were included in the model (Table 3).
The probability of nephropathy for each patient could be
calculated using the equation:
P neph~1 ðÞ ~eazb0X=(1zeazb0X),
where : azb
0X~0:4925z0:1353|1(ADIPOR2(het))z
0:1572|1(ADIPOR2(hom)){0:0137|Age{
0:4843|1(AGER(het))z1:4179|1(AGER(hom))z
2:5223|1(CCL5(het)){2:9026|1(ADIPOR2(het))|1(CCL5(het)){
0:00591|YearsDMz0:0332|1(AGER(het))|YearsDM{
0:0251|1(NOS3(het)){0:7647|1(NOS3(het))|1(ADIPOR2(hom)){
0:3308|1(NOS3(hom)){1:3251|1(NOS3(hom))|1(ADIPOR2(het))z
1:4467|1(NOS3(hom))|1(AGER(het)){0:6859|1(Gender(fem))z
0:7274|1(ADIPOR2(het))|1(Gender(fem))z1:1368|1(ADIPOR2(hom))|
1(Gender(fem))z0:8907|1(hspg2(het)){0:0383|1(hspg2(het))|
YearsDMz0:9661|1(hspg2(hom)){0:1090|1(typedm(T1DM)){
0:0615|1 Origin01 Ashk ðÞ ðÞ {0:9075|1(typedm(T1DM))|1 Origin01 Ashk ðÞ ðÞ
The individual contribution of each of the significant single or
interaction terms is shown in Figure 1. The C statistic was 0.672,
indicating this model has reasonably good predictive ability
(Figure. 2A).
To determine the impact of the genetic data on the model, we
repeated the analysis using only the ‘‘conventional’’ variables (age,
duration of diabetes, diabetes type, sex and ethnicity). In this case, the
best model preserved only 2 conventional variables (age and diabetes
type) and no interactions (Table 3). For this model, the C statistic was
considerably lower (C=0.569) indicating that the genetic data
improved prediction over the conventional model (Figure 2A).
Model Validation
The primary population of 1274 individuals was divided
randomly into 2 unequal groups. The same model was rebuilt
on the larger group consisting of 75% of the population (training
set). The model showed a similar predictive ability when compared
to the original one (C=0.678) (Figure 2B). The ORs estimates of
each variable in the rebuilt model were similar to and in the same
direction as those in the original model. The model was then tested
on the remaining 25% of the population and demonstrated similar
predictive ability (C=0.630) (Figure 2B).
A second validation experiment was performed on an indepen-
dent population, also ascertained in Israel, but from a more
restricted ethnic background (Ashkenazi Jews only). Although the
ROC curve in the replication independent dataset was somewhat
lower than that in the original dataset (Figure 3), we further
evaluated the strength of our model, by testing it for associationwith
nephropathy at two probability cut-offs; one corresponding to the
minimal total type I and type II errors and the other corresponding
to equal errors of both types (Figure 4). The model, which contains
both the genetic and the conventional predictive variables, was
associated with nephropathy in this population when the minimum
error cut-off was used (x
2=17.79, p,0.0001), whereas the
‘‘conventional model’’ was not (x
2=3.27, p,0.071; Table 4). The
associationofthemodelwith nephropathyusingtheequalerrorcut-
off gave similar results (data not shown).
Discussion
In this proof-of-concept study, we demonstrate that incorpora-
tion of multiple genetic variants, conventional risk factors and their
two-way interactions into a logistic model enhances our ability to
predict diabetic nephropathy.
Variants were selected based on previous publications that
demonstrated significant association with diabetic nephropathy, in
most cases in multiple populations of various ethnic groups.
Figure 2. Receiver Operating Characteristic (ROC) curves in the original population. A. Predictive ability of the full and ‘‘conventional’’
models in the original population. ROC Curve and area under the curve (C Statistic) for ‘‘full’’ model (solid line; C=0.672) and for the ‘‘conventional’’
model (dotted line; C=0.569). B. Validation of the model on original population. The ROC Curve and area under the curve (C Statistic) for the model
built on 75% of the original population (solid line; C=0.678) and applied to the remaining 25% of the population (dotted line; C=0.630). The
diagonal line indicates zero predictive value of model.
doi:10.1371/journal.pone.0018743.g002
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18743Therefore, although none of these SNPs had been tested in the
Ashkenazi or Sephardic Jewish populations, the prior probability
that at least some would be associated with nephropathy in our
population was high. We observed significant or nearly significant
association with nephropathy for 5 of the 27 SNPs tested. While
none of these survived Bonferroni correction for multiple testing
(alpha,0.002), the probability of at least 5/27 loci being
significant at the 0.05 level by chance is 0.01.
Figure 4. Graph of type I vs type II error. The solid line indicates the false positive rate (FP, error type I), the dashed line the false negative rate
(FN, error type II) and the dotted line represents the sum of false positive and false negative rates at each probability level. The minimal errors sum is
0.7427 with probability of 0.3368.
doi:10.1371/journal.pone.0018743.g004
Figure 3. ROC Curve and area under the curve (C Statistic) for the ‘‘full’’ model in the replication dataset (dotted line; C=0.576). The
ROC curve and C statistic for the same model in the original population (see Figure 1A) is shown for comparison (solid line).
doi:10.1371/journal.pone.0018743.g003
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population is expected for several reasons. First, our primary
population was modest in size and therefore power (e.g. less than
80% power to detect association with a SNP with an OR ,1.36,
minor allele frequency of 50% and alpha =0.05). Furthermore,
although most SNP selection was based on studies in European
Caucasians, of which the Jewish populations are considered sub-
groups, significant genetic differences between these populations
have been demonstrated [33,34,35]. Finally, some SNPs were
selected based on studies in Japanese [36], African-American and
Scandinavian (Finnish, Swedish) populations, which are likely to
differ considerably from the populations studied here.
The conventional variables that were used for adjustment to
estimate the main effect of the SNPs were age, sex, ethnicity,
diabetes type and duration. Glycemic control was not included
since HbA1c at time of ascertainment is not expected to accurately
reflect overall glycemic insult to the kidneys and historical data was
not available. We did not include hypertension as an independent
predictor because there is a reciprocal relationship between the
hypertension and nephropathy, so that hypertension increases the
risk of nephropathy, while nephropathy itself can cause hyperten-
sion. Thus, in this cross-sectional study, the presence of
hypertension could be the cause or the effect of nephropathy.
Furthermore, the goal of genetic prediction of disease is to identify
at-risk individuals before they develop co-morbidities such as
hyperglycemia and hypertension.
We then tested our hypothesis that a robust predictive model can
be generated by simultaneously taking into consideration multiple
variables as well as possible interactions between them. Though
variables that have no independent effect could interact together to
produce a significant effect, we elected to use a more conservative
approach and selected for our model only those SNPs that had a
nominallysignificantor nearly significant independent impact onrisk.
There are different ways by which multiple variants, genetic and
‘‘conventional’’, can be combined to obtain a composite risk score.
Several investigators have utilized an allele counting method in
which each individual is ranked according to the number of risk
alleles she/he carries in a particular set of loci, sometimes
including factors that reflect the relative strength of the effect of
each SNP [37,38,39,40,41,42]. However, this method fails to take
Table 4. Model prediction based on minimum Alpha+Beta error.
min(Alpha + beta) (prob.=0.3368)
Full model including SNPs Original population x2 90.74
p-value ,0.0001
Sensitivity 82.96%
Specificity 42.77%
Kappa 0.2265
75% training subset x2 63.56
p-value ,0.0001
Sensitivity 85.20%
Specificity 38.54%
Kappa 0.2136
25% test subset x2 14.69
p-value 0.0001
Sensitivity 82.18%
Specificity 39.45%
Kappa 0.1660
Replication population x2 17.79
p-value ,0.0001
Sensitivity 64.26%
Specificity 51.14%
Kappa 0.1319
min(Alpha + beta) (prob.=0.3957)
Conventional model without SNPs Original population x2 16.9304
p-value ,0.0001
Sensitivity 64.55%
Specificity 46.54%
Kappa 0.1018
Replication population x2 3.2673
p-value 0.0707
Sensitivity 36.49%
Specificity 69.51%
Kappa 0.0601
doi:10.1371/journal.pone.0018743.t004
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this shortcoming, we created a logistic model that both takes into
consideration the relative contribution of each factor and allows
for two-way interactions. The resulting model utilized all 5 SNPs,
all ‘‘conventional’’ variables and two-way interactions.
The model that we produced predicted nephropathy with a C-
statistic of 0.672, which although not sufficiently high to be used
clinically, compares favorably with published predictive models for
T2DM and other complex disease [39,40]. In sharp contrast to
what was recently reported for T2DM [38,39], our model relies
heavily on the genetic component, in that removal of these factors
causes the C-statistic to drop markedly. It is highly likely that a
model based on a larger number of genetic variants will provide
much improved prediction of disease, although theoretical studies
suggest that predictive capability that will be of direct clinical
utility may not be possible [43].
To determine the robustness of our model, we performed 2
independent replication analyses.F i r s t ,w er a n d o m l yd i v i d e do u r
original population into two groups, a ‘‘training set’’ and a ‘‘test set’’
and showed that the model was robustly replicated in both subsets
without loss of power or sensitivity (Table 4). Our second method of
replication involved an independent, albeit ethnically related,
population ascertained in Israel. This population differed from our
initial population in that it contained only Ashkenazi Jews, as opposed
to 67.7% Ashkenazi in the original population. Furthermore, a larger
percentage of the replication population had T1DM and the patients
with T2DM were significantly younger. Although the sensitivity and
the C-statistic decreased, which is expected in a replication population
that this not identical to the original population, significant association
withnephropathywasstillobserved (x
2=17.79, p,0.0001),providing
further support for the model. As expected, the ‘‘conventional’’ model,
lacking genetic factors, was not significantly associated with
nephropathy in the replication population.
Although we selected our candidate genes based on their
involvement in known metabolic pathways thought to be important
for the pathogenesis of nephropathy, thus hoping to enhance the
probability of finding significant interactions, the rest of the
modeling was performedwithoutanyintervention,with interactions
selected on the basis of statistical and not physiologic criteria.
Somewhat surprisingly, although our model did identify several
statistically significant two-way interactions, none of these was
expected based on a known physiological relationship. Interactions
that were identified by the model could point to the existence of
heretofore unknown functional relationships. In our model, the
strongest interaction appears to involve the ADIPOR2 and CCL5
variants. The CCL5 SNP natural log odds ratio estimate was 2.52
(Table 3), whereas ADIPOR2 did not show any contribution in the
model as an independent factor. However, in the framework of the
model, the effect of CCL5 SNP is entirely cancelled and even
reversed by the presence of the ADIPOR2 variant (-2.90). If this
statistical interaction does reflect a physiologic relationship between
these 2 genes, the mechanism is not evident. Thus, further studies
are needed to determine if this interaction represents a true
functional relationship and if so, how this impacts our understand-
ing of the pathophysiology of diabetic nephropathy.
In conclusion, by studying the association between a limited
panel of genetic variants and nephropathy risk, we developed a
robust multifactorial logistic regression model to predict nephrop-
athy in our study populations. This approach is unique since
conventional factors were included in the model and not used only
for adjustment, the impact of genetic and conventional factors was
weighted according to their effect and all possible two-way
interactions were allowed (genetic x genetic, genetic x conven-
tional, conventional x conventional). Increasing the number and
spectrum of variants tested would likely improve the predictive
strength of the model. Use of such multifactorial models, including
interactions, may pave the way to prediction of diabetic
nephropathy and other complex genetic diseases in other
populations. Our data in the replication population suggests that
some factors in the model may be ethnicity, age or disease type
dependent, indicating that the development of robust, highly
predictive models may require specific adaptation of the models to
different ethnic groups. They also suggest, however, that once a
model is developed for a specific ethnic group, it is likely that it can
be validly applied to individuals in other subsets of the same or a
closely related ethnic group, further suggesting that if a highly
predictive model could be developed it would be clinical useful.
The ability to accurately predict the risk of nephropathy could
impact the treatment approach on a patient-specific basis, thus
reducing costs and increasing efficacy of individual therapeutic or
preventive interventions. Furthermore, these findings may help
develop a better understanding of the pathophysiology of
nephropathy, thus leading to novel treatment approaches.
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